CAPSTONE-1
Regimen
- Experimental
- adebrelimab (SHR-1316) + carboplatin + etoposide
- Control
- placebo + carboplatin + etoposide
Population
Treatment-naive extensive-stage small-cell lung cancer (Chinese population)
Key finding
mOS 15.3 vs 12.8 mo (HR 0.72, 95% CI 0.58-0.90, one-sided P=0.0017)
Source: PMID 35576956
Timeline
Guideline citations
- CSCO SCLC 2025 (p.64)⚠️ OCR source